VIA
SUPN icon

Virtus Investment Advisers’s Supernus Pharmaceuticals SUPN Stock Holding History

Virtus Investment Advisers’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-29,148
Closed -$780K – 373
2024
Q2 		$780K Hold
29,148
– – 0.66% 41
2024
Q1 		$994K Hold
29,148
– – 0.71% 33
2023
Q4 		$844K Hold
29,148
– – 0.63% 38
2023
Q3 		$804K Hold
29,148
– – 0.55% 43
2023
Q2 		$876K Buy
29,148
+6,716
+30% +$235K 0.6% 38
2023
Q1 		$813K Buy
+22,432
New +$863K 0.57% 48

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Virtus Investment Advisers's SUPN Position: Q3 2024 in Review

Virtus Investment Advisers sold out of Supernus Pharmaceuticals (SUPN) in Q3 2024, closing a stake of 29,148 shares — an estimated $780K sold.

Virtus Investment Advisers first reported a position in SUPN in Q1 2023 and held it in 6 quarters. The position peaked at $994K in Q1 2024. 273 funds tracked by Wall St. Rank hold SUPN as of Q3 2024.

  • Virtus Investment Advisers reported no remaining Supernus Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Virtus Investment Advisers sold 29,148 Supernus Pharmaceuticals shares in Q3 2024, an estimated $780K.
  • Virtus Investment Advisers first reported a position in Supernus Pharmaceuticals in Q1 2023 and held it in 6 quarters.
  • Virtus Investment Advisers's Supernus Pharmaceuticals position peaked at $994K in Q1 2024.
  • 273 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2024.

Based on Virtus Investment Advisers's 13F filing for Q3 2024, filed 14 Nov 2024.